Format

Send to

Choose Destination
Nat Rev Cancer. 2016 Feb;16(2):121-6. doi: 10.1038/nrc.2016.2.

Acquired resistance to immunotherapy and future challenges.

Author information

1
Center for Cancer Research, National Cancer Institute and Center for Regenerative Medicine, National Institutes of Health, Bldg 10/CRC, Room 3-5762, 9000 Rockville Pike, Bethesda, Maryland 20892, USA.
2
Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Brisbane, Queensland 4006, Australia; and the School of Medicine, University of Queensland, Herston, Brisbane, Queensland 4006, Australia.
3
Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, New York 10065, USA.

Abstract

Advances in immunotherapy have resulted in remarkable clinical responses in some patients. However, one of the biggest challenges in cancer therapeutics is the development of resistant disease and disease progression on or after therapy. Given that many patients have now received various types of immunotherapy, we asked three scientists to give their views on the current evidence for whether acquired resistance to immunotherapy exists in patients and the future challenges posed by immunotherapy.

PMID:
26822578
PMCID:
PMC6330026
DOI:
10.1038/nrc.2016.2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center